
|Slideshows|March 2, 2017
ACTRIMS 2017 Forum: MS Treatment Clinical Trials
Author(s)Samantha J. Peterson
Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.
Advertisement
Presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum included a 10-year follow-up of patients after mitoxantrone treatment, a comparison of no evidence of disease activity in patients treated with ocrelizumab or IFN β-1a, and an evaluation of no evidence of progression in a trial of patients administered ocrelizumab or placebo.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Expands Indication for n‐Butyl Cyanoacrylate in Chronic Subdural Hematoma
2
Exploring the Integration of AI into the field of Epilepsy: Balu Krishnan, MD
3
What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers
4
A Clinical Review of the 2025 Restless Leg Syndrome Guidelines
5




















